OBJECTIVES:
- To detect antibodies against NF155, nodal neurofascins (NF140, NF186) and CNTN1 in CIDP patients from a clinical trial(ICQ).
SAMPLES:
- For CNTN1: 0701-00893 (30), 0702-00867 (31), 0702-00872 (32), 0702-00906 (33), 0802-00903 (34), 0302-00907 (5), 0404-0899 (8), 0502-00886 (9), 0503-00908 (10), 0902-00887 (17), 0903-00852 (19), 0903-00856 (21), positive control.
- For NF140-186: 0701-00893 (30), 0702-00867 (31), 0702-00872 (32), 0702-00906 (33), 0802-00903 (34), 0302-00907 (5), 0404-0899 (8), 0502-00886 (9), 0503-00908 (10), 0902-00887 (17), 0903-00852 (19), 0903-00856 (21), positive control.
- For NF155:, 0701-00893 (30), 0702-00867 (31), 0702-00872 (32), 0702-00906 (33), 0802-00903 (34), 0302-00907 (5), 0404-0899 (8), 0502-00886 (9), 0503-00908 (10), 0902-00887 (17), 0903-00852 (19), 0903-00856 (21), positive control.
ICC CNTN1:
Blocking solution: Rabbit serum in PBS.
- Patient’s sera diluted 1/100 in rabbit sèrum in PBS.
- Primary antibody: anti-CNTN1 diluted 1/1000.
- Secondary antibodies: RAG 488 + RAH 594 (1/1000)
- Vectashield mounting medium.
ICC NF155/NF140/NF186:
Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 in 5% goat serum in PBS.
- Primary antibody: anti-NF diluted 1/1000.
- Secondary antibodies: GAC488 + GAH 594 (1/1000).
- Vectashield mounting medium
RESULTS: all the samples were negative. The cntn1 wells hadn’t got cells.
